bearish

SillaJen Inc

SillaJen Inc (215600 KS): Baselia Deal Enriches Pipeline; Stock Trading Resumption Decision Soon

Despite recent acquisition of a first-in-class oncology drug candidate, SillaJen is a risky bet amid regulatory crackdown and past clinical trial setback suffered by lead drug candidate.

Equity Bottom-Up
304 Views, 23 Sep 2022 19:16
SUMMARY(Sign Up to Access)
or
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
x